| INTRODUCTION
In 2016, there are expected to be 180 890 new cases of prostate cancer (PCa), along with 26 120 deaths from the disease, making PCa the most commonly diagnosed non-skin cancer among men in the United States and the second leading cause of cancer death among men. 1 Studies of obesity and PCa incidence have found positive, negative, and null associations. [2] [3] [4] [5] [6] [7] [8] [9] A meta-analysis found a modest increase in risk with increasing BMI, RR = 1.05 (95%CI 1.01-1.08) per five unit increase in BMI. 2 However, analyses by grade and stage suggest that obesity is more strongly associated with advanced PCa and unassociated with or perhaps even protective against localized or low-grade disease. 2, 5, 10 However, obesity is associated with lower PSA, a thorough digital rectal exam may be more difficult to complete in obese men, and obesity is related to larger prostate size and potentially reduced sensitivity for biopsy based diagnoses. [11] [12] [13] [14] Therefore interpretation of the extant literature on obesity and PCa incidence is complex. 13 It has been argued that because prostate size is larger among overweight and obese men as compared to normal weight men the diagnostic accuracy of biopsies for detecting prostate cancer is lower in overweight and obese men. This in turn effects epidemiologic studies of obesity and PCa risk that may suffer from diagnostic bias
The Prostate. 2017;77:949-954. wileyonlinelibrary.com/journal/pros with under-diagnosis of small non-aggressive tumors among obese men. 13, [15] [16] [17] Within a studied PCa case-series, the sub-group of men with larger prostates and higher BMI may include a higher percentage of men diagnosed with aggressive tumors whose tumors were missed at prior biopsies when the tumors were smaller and/or less aggressive. 13 This phenomena would lead to an overestimate of the association between obesity and diagnosis of aggressive prostate tumors and an underestimate of the association between obesity and non-aggressive PCa. Furthermore, depending on the underlying distribution of aggressive and non-aggressive cancers in population the study draws cases from, this type of diagnostic bias could lead to a failure to observe a link between obesity and overall PCa risk.
Past research that has incorporated measures of prostate size into studies of obesity and PCa have derived cross-sectional casecontrol studies from series of men undergoing biopsy during a specified time period; men whose biopsy returns a finding of cancer are cases and men whose biopsy returns a benign finding are treated as controls. [15] [16] [17] In these studies prostate size is measured at the time of biopsy when case-control status was ascertained. [15] [16] [17] 15, 17 Here using a prospective cohort design we measured prostate size at entry into the cohort and assessed its role as an effect modifier or confounder of the relationship between obesity and PCa risk.
| MATERIALS AND METHODS
This nested case-control study has been extensively described previously. 8 regression models were used to estimate odds ratios for PCa incidence during follow-up for overweight and obese men compared to normal weight men and the analyses adjusted for baseline PSA and a family history PCa. To adjust for possible differences in screening intensity between obese, overweight, and normal weight men, analyses also adjusted for the number of PSA tests and DRE during follow-up. 8 As it is highly unlikely that a prostate biopsy is undertaken without a PSA test and/or DRE, adjustment for screening intensity during follow-up is expected to control for differences in surveillance, biopsy rates, and overall contact with the medical system that might exist between men of different body sizes. This model is considered the baseline model and estimated the odds ratios for PCa incidence associated with overweight and obesity status at the initial biopsy without consider- 
| RESULTS
The characteristics of the men included in the analyses are shown in Table 1 . Those missing volume data were significantly older (1.86 years) and had lower PSA levels at biopsy (2.42 ng/mL); men for whom prostate volume data was and was not available did not differ for other variables included in the analyses.
After adjustment for age, race, and PSA level at cohort entry, larger body size was significantly associated with larger prostate volume (see Fig. 1 , P = 0.002 for overweight vs normal weight, and P = < 0.001 for obese vs normal weight). prostates, however the association with PCa risk was stronger for overweight than for obesity (see Table 2 ). Among men with larger prostates there was no association between PCa risk and overweight or obesity and the overweight × prostate volume and the obesity × prostate volume interaction terms were not statistically significant (P = 0.12 and P = 0.59, respectively).
In models that considered prostate volume as a confounder, and PCa risk and adjustment for prostate volume increased the effect sizes for both obese and overweight status; a 23% increase in beta for obesity and a 22% increase in beta for overweight (Table 3 ). Prior to adjustment for prostate volume at biopsy, overweight, and obese status were non-significantly associated with aggressive and nonaggressive PCa (Table 4) . Adjustment for prostate volume increased the effect estimates for overweight (14%) and obesity (17%) for incidence of non-aggressive PCa but did not alter the effect estimates for aggressive PCa. Prostate volume was inversely associated with aggressive PCa but not with non-aggressive PCa (Table 4 ).
| DISCUSSION
As observed in prior studies, in this cohort of men followed up after an initial benign biopsy, a larger body-size was associated with larger prostate volumes at initial biopsy. 13, 15, 16 As prostate volume at benign biopsy was positively associated with body-size and inversely associated with PCa risk during follow-up, prostate volume acted as an inverse confounder biasing unadjusted estimates of the association between body-size at initial benign biopsy and subsequent PCa risk toward the null. As we reported previously, being overweight or obese significantly increased risk for prostate cancer 8 and adjustment for prostate volume at initial benign biopsy further increased these risk estimates.
Prostate volume did not appear to act as a significant effect modifier of associations between body-size and PCa incidence. Similar to Fowke et al, 15, 17 between body size and PCa risk. However, their case-control studies based on biopsy series were both analyzed as a cumulative incidence sampled case-control study in the context of a common outcome, a design that often exaggerates differences in strata specific associations and over estimates interaction effects.
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Overall the analyses suggest that prostate volume primarily acted as an inverse confounder for the incidence of non-aggressive PCa; adjustment for prostate volume modestly increased the OR for obesity for non-aggressive tumors but did not alter the OR aggressive tumors.
This finding is consistent with the idea that larger prostate volumes can obscure the detection of non-aggressive tumors and cause an underestimate of the association between obesity and this sub-set of PCa. 13, [15] [16] [17] Depending on the relative proportion of aggressive and non-aggressive tumors in any studied PCa case-series, bias induced by FIGURE 1 Mean prostate volume and 95% confidence intervals by body size category at cohort entry adjusting for age and PSA level at cohort entry and race failing to adjust for prostate volume may cause a significant underestimate of the effect of obesity on overall PCa risk. Very few prior studies of PCa and body size also have data available on prostate volume and so this confounding effect is generally not accounted for. [15] [16] [17] As such there may be a pervasive underestimation of the association between obesity and overall PCa risk in the literature.
The strengths of this study include its prospective design with prostate volume data available at cohort entry, adjustment for screening intensity during follow-up, and the availability of high quality medical records collected within a single integrated health system. The matching of controls to cases on date of cohort entry and duration of follow-up assures that cases and controls experienced the same temporal trends in medical practice, medical technology, and case management, and have the same period of observation in which screening behaviors can occur. In addition, potential differences in PCa screening intensity by obesity status, that may otherwise have introduced bias into the study, were adjusted for using data on the number of PSA tests and DRE during follow-up. As it is highly unlikely that a prostate biopsy is undertaken without a closely preceding PSA test and/or DRE, adjustment for screening intensity during follow-up is expected to control for differences in surveillance, biopsy rates, and men's engagement with the medical system that might exist between men of different body sizes. Thus the screening intensity adjusted analyses answer the question-conditional on having had the same number of PSA tests and DRE during follow-up are obese men at higher risk of prostate cancer than normal weight men? A caveat for the study is that it was conducted in a high risk population who had already undergone a procedure for suspicion of PCa and thus the results may not be generalizable to the general male population. However, approximately 1 million prostate biopsies are performed annually in the US and two-thirds of these are negative. 22 Thus the study is likely generalizable to a large population of men.
| CONCLUSION
This is the first study to prospectively assess associations between prostate volume and PCa risk and to conduct analyses of body size and | 953
